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1. Introduction 
It is known that cholecalciferol (vitamin Da) is 
first metabolized in the liver and the resulting 25-OH- 
Da is further hydroxylated in the kidney at either 
C-l, C-24 or C-26 position to give 1,25-, 24,25- and 
25,26(OH)sDa, respectively. The latter metabolite, 
initially isolated [l] from hog’s blood, has been 
reported [2] to stimulate selectivity bone mineraliza- 
tion in vitamin Ddeprived rats. Moreover, 
25,26(OH)aDa has been found to be a major dihy- 
droxy-metabolite of cholecalciferol present in human 
plasma, apparently irrespective of vitamin D nutritional 
status and of serum calcium levels [3]. Its contigura- 
tion at C-25,25R or 25S, has remained unknown. 
Recently, tritiated 25,26(Ol-&Da was generated 
enzymatically by chick renal homogenates and was 
shown [4] to be of 25R configuration by HPLco-C 
with synthetic C-25 epimers [5]. A similar identifica- 
tion of 25,26(OH),D, of human origin was highly 
desirable and depended upon the availability of a 
material with adequate radioactivity. 
This report describes the preparation of tritiated 
human 25,26(OH)aDs and its identity with synthetic 
25R ,26(OH)*D, established by HPLco-C of their 
3,25,26-Tris-TMS derivatives by a procedure described 
in [4]. 
Abbreviations: 25-OH-D3, 25-hydroxycholecalciferol; 
1,25(OH),D,, 1,25dihydroxycholecalciferol; 24,25(OH),D,, 
24,25dihydroxycholecalciferol; 25,26(OH),D,, 25,26- 
dihydroxycholecalciferol; TMS, trimethylsilyl; HPL(co-)C, 
high pressure liquid (co-)chromatography 
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2. Experimental 
2.1. Instmmenls 
A Waters Associates HPLC Chromatograph with a 
254 nm ultraviolet detector and a 30 cm X 4 mm i.d. 
column of /,.t Porasil was used. The mobile phase was 
n-hexane containing either 2.0% or 2.5% (v/v) 
dichloromethane at a 1 ml/mm flow rate. 
The radioactivity was detected using a counting 
solution (Liquid Scintillator Unisolve 1, Koch-Light 
Lab.) and a liquid scintillation counter (Intertechnique 
Model SL 40). 
2.2. Preparation and purification of human radio- 
active 25,26(OH)aa 
Plasma (2.5 1) was obtained from a patient under- 
going plasmapheresis for macroglobulinaemia. The 
patient had received 24 h previously an intravenous 
injection of 10 &i [ 1,2-‘H]vitamin D3 (12.3 Ci/ 
mmol, Radiochemical Centre, Amersham) in 1 .O ml 
ethanol, dispensed in 9.0 ml Intralipid (Vitrum, 
Stockholm). The nature of the investigation had been 
fully explained to the patient, who gave his informed 
consent to the procedure. 
The plasma was extracted in aliquots using chloro- 
form and methanol [6]; the extracts were combined 
and applied to columns of Sephadex LH-20 (1.4 X 
50 cm) eluted with chloroform-n-hexane (13 :7, v/v) 
[7]. The fractions eluted between 260 and 300 ml 
were collected, pooled and applied to a new column 
of the same type; the same fraction was collected. 
The residue from this fraction, which contained both 
25,26(OH),D, and 1 ,25(OH)aD3, was further purified 
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by HPLC using a column of Spherisorb S SW silica 
(0.45 X 10 cm, Anachem. Ltd), developed with a 
solvent mixture of dichloromethane-methanol 
(100:2, v/v) at a 1.3 ml/min flow rate. In this system 
25,26(OH),D, was eluted between 8 and 12 min and 
1,2S(OI-l)2D, between 12 and 16 min [8]. The puri- 
fied 2S,26(OH)2D3 fraction from human plasma con- 
tained 6.7 nCi 3H and was used for co-chromatography 
with the synthetic material as described in sections 
2.3 and 2.4. 
2.3. Prepamtion of 3,2.5,26-Tris-TMS derivatives of 
25,26(OH)@3 
A mixture of synthetic [S] 2SR,26- and 
2SS,26(OH),D, (1 .S Kg each) was treated with 
trimethylsilylimidazol(4 ~1) in n-hexane (100 ~1) at 
50°C for 30 min and left at room temperature for 
48 h. The solution was then injected into HPL 
chromatograph. 
2.4. Co-chromatography with radioactive human 
25,26(OH)2& 
In experiments with 25 ,26(OH)2-[1 ,2?H]Ds 
isolated from human plasma, the radioactive material 
was added to the mixture of epimeric 2SR,26- and 
2SS,26(OH),D, and treated as above. Fractions were 
collected at 1 min intervals and the radioactivity 
determined in each fraction. 
3. Results 
Separation of the Tris-TMS derivatives of 2SS,26- 
and 2SR ,26(OH),D, was carried out by HPLC on 
high surface area silica with n-hexane containing 
either 2% or 2.5% dichloromethane. The retention 
time for the 25s and 2SR epimers, respectively, was 
91 and 95 min with the former, and 54 and 56 min 
with the latter, solvent mixtures. The resolution of 
epimers was better with 2% dichloromethane-n- 
hexane (fig.lB), but was distinctly apparent using 
2.5% dichloromethane-n-hexane (fig.lA). 
In experiments with human 2S,26(OH),-[1,2-‘HI- 
D3 the radioactivity clearly migrated with the deriva- 
tive of 2SR ,26(OI&D, (the more polar peak) using 
both solvent systems (fig.lA,B). Recovery for the 
radioactivity was 7 1%. 
4. Discussion and conclusion 
The TMS-derivatives of human 25,26(OH&[ 1,2- 
3H I D3 co-migrated by HPLC with the more polar 
C-25 epimer: 2SR,26(0H)2D3-Tris-TMS in two 
lime (min.) 
( 400 
I 300 
Fig.1. Separation of the Tris-TMS ethers of 25R,26- and 25&26(OH),D,. and co-chromatography of the T&TINS ether of human 
radioactive 25,26(OH),D,. with the 25R,26(OH),D,. derivative (the more polar peak). Chromatography was performed with: (A) 
2.5% dichloromethane-n-hexane; (B) 2% dichloromethane-n-hexane. The clear bars represent radioactivity in each fraction. 
OD = absorbance. 
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solvent systems: 2% dichloromethane-pl-hexane and 
2.5% dichloromethane-n-hexane. Since this identity 
was recorded with two mobile phases of various capa- 
cities, the retention time increasing by -70% with the 
less polar solvent, an artefact due to isotopic’separa- 
tion of the tritiated compound by HPLC [9] appears 
unlikely. 
We have shown conclusively, that 25,26(OH),Da 
isolated from human plasma and 25,26(OH),Da 
biosynthetically generated by chick renal homogenates 
are identical and have a 25R configuration. 
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